Improvements in health‐related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity-Reference-Cited by-同舟云学术

Improvements in health‐related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity

Published:2017-10-16 Issue:1 Volume:8 Page:1-10
ISSN:1758-8103
Container-title:Clinical Obesity
language:en
Short-container-title:Clin Obes

Author:

Kolotkin R. L.¹²³⁴⁵,Smolarz B. G.⁶,Meincke H. H.⁷,Fujioka K.⁸

Affiliation:

1. Quality of Life Consulting Durham NC USA

2. Department of Community and Family MedicineDuke University Medical Center Durham NC USA

3. Department of Health StudiesWestern Norway University of Applied Sciences Førde Norway

4. Førde Hospital Trust Førde Norway

5. Morbid Obesity CentreVestfold Hospital Trust Tønsberg Norway

6. Novo Nordisk Inc. Plainsboro NJ USA

7. Novo Nordisk A/S Bagsvaerd Denmark

8. Nutrition and Metabolic Research Center Scripps Clinic Department of Endocrine La Jolla CA USA

Funder

Novo Nordisk

Publisher

Wiley

Subject

Endocrinology, Diabetes and Metabolism

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cob.12226

Reference28 articles.

1. The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysis

2. Meta-analysis of the association between body mass index and health-related quality of life among adults, assessed by the SF-36

3. KolotkinRL AndersenJR.A systematic review of reviews: exploring the relationship between obesity weight loss and health‐related quality of life.Clinical Obesity2017.https://doi.org/10.1111/cob.12203.

4. The George Washington University. Obesity drug outcome measures: a consensus report of considerations regarding pharmacologic intervention. [WWW document]. Accessed 4‐11‐17.

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Obesity pharmacotherapy in older adults: a narrative review of evidence;International Journal of Obesity;2024-05-06

2. Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond;Metabolism;2024-02

3. Consensus on pharmacological treatment of obesity in Latin America;Obesity Reviews;2023-12-20

4. Russian development for drug independence in endocrinology: comparative analysis of bioequivalence, safety and tolerability of the first domestic liraglutide;Pharmacy & Pharmacology;2023-11-20

5. The improved health utility of once‐weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1‐4 obesity trials;Diabetes, Obesity and Metabolism;2023-05-08